Rehan Saleem, MD
Psychiatry · Midlothian, VANPI 1447216668
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $18,330 of the $27,938 with a category attached, or 65.6%. 32 manufacturers reported payments, led by AbbVie at 40.2% of the total. 2025 is the largest year on record at $12,593, 6.4 times the $1,969 reported in 2019. Among psychiatry clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,263 payments — averaging $22.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$11K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Lundbeck LLC$1K
- Neurocrine Biosciences, Inc.$1K
- plus $9K from 26 others
What the payments were for
- Consulting fees$1,4005%
- Speaking & faculty fees$8,00029%
- Travel & lodging$110%
- Food & beverage$18,33066%
- Education$1981%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$8,248
- TRINTELLIX$1,400
- REXULTI$361
- INGREZZA$259
- Fanapt$247
- SPRAVATO$125
- PADCEV$125
- Quillivant$125
- Dyanavel XR$125
- Quillichew ER$125
- Austedo XR$125
- JOENJA$125
- AUSTEDO$123
- Auvelity$122
- CAPLYTA$103
How this compares
$27,938 in reported general payments places this provider in the 95th percentile of 884 psychiatry providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 15 | $61,326 |
| RexultiBrexpiprazole | 15 | $26,975 |
| VraylarCariprazine Hcl | 14 | $20,430 |
| TrintellixVortioxetine Hydrobromide | 38 | $20,335 |
| Aripiprazole | 146 | $20,299 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 63 | $6,582 |
| Bupropion XlBupropion Hcl | 208 | $5,357 |
| Duloxetine Hcl | 165 | $4,037 |
| Divalproex Sodium ErDivalproex Sodium | 34 | $3,477 |
| Mirtazapine | 204 | $2,958 |
| Doxepin Hcl | 15 | $2,856 |
| Lamotrigine | 207 | $2,704 |
| Quetiapine Fumarate | 168 | $2,289 |
| Vilazodone Hcl | 21 | $2,107 |
| Methylphenidate Hcl | 58 | $1,796 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $844 | $61,32615 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,664 | $26,97515 claims |
| AbbVieVraylar | $11,226 | $20,43014 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $2,400 | $20,33538 claims |
| Almatica Pharma LLCSertraline Hcl | $182 | $1,107159 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 884 psychiatry providers in Virginia.
Other psychiatry in Midlothian
- Adam KaulMidlothian$20K
- Kemberly ClarkMidlothian$11K
- Jagdeep KahlonMidlothian$8K
- Niku SinghFalls Church$2.5M
- David ScheidererRoanoke$2.4M
- Kent McDanielGlen Allen$2.1M
- Jasdeep MiglaniManassas$958K
- David SpiegelNorfolk$565K
- William YetterVirginia Beach$312K
- Anita ClaytonCharlottesville$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.